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Multiple factors have been shown to alter intestinal microbial diversity. It remains to be seen, however, how
multiple collective pressures impact the activity in the gut environment and which, if any, is positioned as a
dominant driving factor determining the final metabolic outcomes. Here, we describe the results of a
metabolome-wide scan of gut microbiota in 18 subjects with systemic lupus erythematosus (SLE) and 17
healthy control subjects and demonstrate a statistically significant difference (p , 0.05) between the two
groups. Healthy controls could be categorized (p , 0.05) based on their body mass index (BMI), whereas
individuals with SLE could not.We discuss the prevalence of SLE comparedwith BMI as the dominant factor
that regulates gastrointestinal microbial metabolism and provide plausible explanatory causes. Our results
uncover novel perspectives with clinical relevance for human biology. In particular, we rank the importance
of various pathophysiologies for gut homeostasis.
O
ur commensal microbiota is a plastic ‘‘organ’’ comprised of trillions of microbes with symbiotic func-
tional capabilities that directly affect human health. Important studies on the relationship of intestinal
microbiota with diseases have linked profound changes in the composition of the population and
metabolic functions of the gut microbiota to common human intestinal disorders, such as obesity1, Crohn’s
disease and colitis-associated colorectal carcinoma2, ulcerative colitis and irritable bowel syndrome1, and
Clostridium difficile-associated diarrhea3,4. Recent studies have also suggested that factors, such as antibiotic
treatments4,5 and diet6, and subject characteristics, such as age7, may be involved in alterations in the microbiota.
Researchers are beginning to recognize and understand the short- and long-term consequences of these
changes5,7–9.
Although evidence has suggested an additional link between gut microbiota and immune disorders10, this
relationship remains incompletely understood. In a previous work, a relevant intestinal dysbiosis was described in
the prototypical auto-immune disease systemic lupus erythematosus (SLE)11. This microbial imbalance was
characterized by increased Bacteroidetes levels and a lower Firmicutes/Bacteroidetes ratio. Metagenome func-
tional inference highlighted putative metabolic processes that were potentially associated with SLE patients, such
as an overrepresentation of glycan metabolism and oxidative phosphorylation. However, although this in silico
analysis could be correlated with a higher abundance of some specific bacterial groups in lupus (i.e.,
Bacteroidetes), experimental evidence of the overall gut microbiota functionality in SLE patients is lacking. In
this report, a metabolome-wide scan of the gut microbiota in patients (n 5 18; SLE codes) with the prototypical
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auto-immune disease SLE12 and healthy controls (HC codes; n 5 17)
is presented. The aim was to discuss primarily whether SLE plays a
role in shaping the metabolism of gastrointestinal microbiota, and if
so, to obtain information on the cause and effect relationship between
the altered microbial metabolites and the underlying disease. This
study should be of relevance because patients with SLE exhibit a
marked predisposition to metabolic syndrome13, atherosclerosis14,
renal and urinary dysfunctions13,15, and insulin resistance15, and some
of these disorders have been linked to gastrointestinal microbiota16,17.
These results demonstrate a separation between the chemical com-
positions of gut microbiota of both the SLE and HC groups, which
was not observed by examining the taxa abundance and composition
of their corresponding microbiota. In addition, body mass index
(BMI) was shown to have a remarkable effect in healthy subjects
although having no effect in patients with SLE, which suggests that
the auto-immune response is a stronger driver of intestinal dysbiosis
than obesity.
Results
Study cohorts. SLE patients (n 5 18) were recruited from the updated
Asturian Register of Lupus. All patients fulfilled at least four of the
American College of Rheumatology criteria for SLE11. All were women
of Caucasian descent (49.1 6 9.7 years old) with no active disease at
the time of sampling (Systemic Lupus Erythematosus Disease Activity
Index (SLEDAI) score#8). Information on the clinical manifestations
of the disease was obtained from the individual clinical records (Sup-
plementary Table 1). Only individuals who had not used antibiotics,
glucocorticoids, immunosuppressive drugs, monoclonal antibodies, or
other immunotherapies in the 6 months prior to enrollment were
recruited for the study. Seventeen gender- and age-matched healthy
controls (HC codes) were recruited from the same population. To
reduce the possibility that our assay was affected by factors known
to influence the gut microbial profile, such as age, diet, and medi-
cations, patients with similar factors were selected. These factors in-
cluded gender (all study subjects were women); age; the absence of
antibiotics, steroids, and immunological treatments; medical history
(presenting with a wide variety of clinical SLE manifestations); disease
duration (2–24 years); and an absence of flares of disease activity at the
time of sampling (Supplementary Table 1). Additional factors also
included the mean dietary intake of energy, macronutrients, micro-
nutrients, fiber, and phyto compounds (Supplementary Table 2) and
lifestyle-related factors (smoking, alcohol consumption, physical acti-
vity, and use of vitamin and mineral supplements). The complete
datasets together with body mass index (BMI) values for each of the
investigated individuals are presented in Supplementary Table 3.
Contribution and prevalence of SLE in gut homeostasis.Our study
protocol comprised the isolation of metabolites from microorganisms
obtained from fecal material followed by ametabolome-wide scan via a
combination of mass spectrometry (MS) with liquid chromatography
(LC) and capillary electrophoresis (CE) separations. Of 134,312masses,
a total of 955 (LC-MS positive mode: 331; LC-MS negative mode: 549;
CE-MS: 75) fulfilled statistical criteria for selection (p value ,0.05;
Mann-Whitney U test or t-test; Supplementary Table 4). A scatter
plot based on principal component analysis scores obtained from
this set of compounds revealed a clear separation between the SLE
and HC groups (Figure 1). Mass signals were highly similar in all
SLE patients regardless of age, BMI, disease duration, dietary intake,
lifestyle-related factors, or medical history (Supplementary Tables
1–3). Interestingly, the HC group was divided into two distinct sub-
groups (Figure 1). A total of 572 of the 134,312 masses (LC-MS
positive mode: 155; LC-MS negative mode: 352; CE-MS: 65) caused
this separation (p , 0.05; Supplementary Table 4). Regardless of age,
dietary intake and lifestyle-related factors (Supplementary Tables 2
and 3), HC subjects with BMIs ranging from 20.19 to 24.83 kg/m2
formed Cluster 1, whereas those with BMIs ranging from 25.24 to
36.92 kg/m2 formed Cluster 2. This separation was not observed in
SLE patients (Figure 1), whose BMIs ranged from 19.95 to 37.91 kg/
m2 (Supplementary Table 3).
Taken together, we demonstrate that the immune status of SLE
patients is thus a dominant factor that swiftly regulates the metabo-
lome of the gut microbiota regardless of environmental or individual
characteristics. In contrast, in healthy subjects in whom no stronger
pressure than BMI exists, BMI (e.g., overweight or obesity) becomes
a driving factor determining microbiotal metabolism. The results
provided in Figure 1 suggest that the division of the clusters in HC
subjects occur within a BMI interval ranging from 24.83 to 25.24 kg/
m2, which corresponds to the upper and lower limits of the two
Figure 1 | A principal components analysis (PCA) plot for the models built using the set of filtered data that were present in at least 50% of the quality
controls (QCs) and for which the coefficients of variation were less than 30% across the QCs. A) PCA plot based on LC-MS (1) data: 4 components
(PC3 vs. PC4 shown; no biological variation described by the first two components). B) PCA plot based on LC-MS (2) data: 5 components (PC1 vs.
PC2 shown). C) PCA plot based on CE-MS data: 6 components (PC1 vs. PC2 shown). Statistics (R2 and Q2) are provided in the Figure panels. HC4,
with a BMI of 26.29 kg/m2, located within ‘‘High’’ and ‘‘Low’’ BMI groups was rejected prior to statistical analysis. The ‘‘High BMI’’ cluster was formed
from the following samples (BMI in kg/m2 in parentheses): HC6 (27.19), HC8 (27.40), HC19 (25.24), HC20 (28.82), HC26 (30.92), HC29 (36.90),
and HC33 (25.95). The ‘‘Low BMI’’ cluster was formed from the following samples: HC11 (20.19), HC13 (24.83), HC14 (24.80), HC16 (22.18), HC21
(23.18), HC22 (23.07), HC28 (21.90), HC30 (22.68), and HC32 (23.13).
www.nature.com/scientificreports
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identified clusters (all samples with BMI # 24.83 kg/m2 clustered
together, and samples with BMI $ 25.24 kg/m2 formed a separate
cluster). Note that lean-normal individuals are typically character-
ized by a BMI # 24.99 kg/m2, over-weight individuals by a BMI $
25 kg/m2 (from 25.0 to 29.99), and obese individuals by a BMI $
30 kg/m2 (from 30.0 to 40)18. Therefore, one could assume that an
unknown mechanism triggers the alteration of gut microbiota func-
tionality at the frontier between lean and over-weight host status.
This finding is supported by our previous study in a different popu-
lation of healthy lean and obese individuals showing that the gut
microbiota boosts glycosyl hydrolase activities at a similar BMI range
(i.e., 24.5–25 kg/m2)17. This result is of particular importance as, to
the best of our knowledge, no previous investigation has linked host
BMI to gut microbiota metabolic dynamics in the development of
obesity.
It should be highlighted that a principal coordinate analysis
(PCoA) of SLE and HC subjects, based on 16 rRNA microbiota
profiles, did not result in subcategorized clusters, either between
SLE and HC or between HC subjects with high and low BMI
(Figure 2)11. This suggests that the changes induced by SLE or BMI
(in healthy controls) become marked at the highest level of the func-
tional hierarchy, i.e., the metabolite level (Figure 1), regardless of the
heterogeneities that appear below the functional level, i.e., the level of
microbiotal population structure (or 16S rRNA).
Association of SLEwith chemical compositions in the gutmicrobiota:
explanatory analysis. As mentioned above, only 955 of 134,312 (or
0.72% of the total) mass features statistically (p , 0.05) differed
between the SLE and HC groups, suggesting that the impact of
SLE on the gut microbiotal metabolite-wide flux distribution and
on metabolism itself is moderately low. As we are aware that our
study identifies metabolic signatures (955) associated with immune
status in SLE compared to HC individuals, mechanisms explaining
these associations must be proposed. For this purpose, empirical
formulas were assigned to masses that achieved statistical criteria
(p , 0.05) with a maximum error of 5 ppm using the CEU Mass
Mediator (http://biolab.uspceu.com/mediator). We describe each of
the major effects linked to key chemical species below.
We first observed that SLE patients exhibited reduced levels
of homoserine lactone (HSL) (11.3-fold reduction; p 5 0.001;
Supplementary Table 5). HSL is the degradation product of N-acyl-
HSLs (AHSL) whenmetabolized by AHSL lactonases and acylases19–21.
Figure 2 | Principal coordinate analysis (PCoA) of SLE and HC based on taxa abundance and composition of gut microbiota. Three-dimensional
and bi-dimensional PCoA representation based on a UniFrac similarity matrix of the composition of SLE and HC sample operation taxonomic units
(OTUs) is shown. Percentages shown along the axes represent the proportion of dissimilarities captured by the axes. Total bacterial 16S rRNA data
and taxa abundance were determined as reported11. The raw sequences reported in this article have been deposited in the NCBI Short Read Archive (SRA)
(study accession number: SRP028162). Codes are as shown in Supplementary Table 3.
www.nature.com/scientificreports
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The reduced accumulation of HSL in SLE patients may be related to
an increase in the activity of quorum quenching enzymes that can
decrease the pool of AHSL and thus might attenuate quorum sensing
and cell-to-cell communication and promote disease progression19–23.
Compared toHC subjects, SLE patients also exhibited significantly
reduced levels of N-acetylmuramic acid (MURNAc) (25.0-fold
reduction; p 5 0.00005) and, to a lesser extent, N-acetylglucosamine
(1.5-fold reduction; p 5 0.0004) (Supplementary Table 5). Both are
essential components of the peptidoglycan biopolymer of bacterial
cell walls. Peptidoglycans have long been known to promote an
inflammatory response; thus, lowering the production of peptidogly-
can components, caused by deficiencies in key enzymes24 and/or the
bacteria that express them, has been demonstrated to potentially
influence signaling, disease factors and immune responses16,25,26. In
addition, a series of observations have led to the hypothesis that in
patients with rheumatoid arthritis with a genetic basis, normal intest-
inal microbiota harbor bacteria with cell walls capable of stimulating
rheumatoid factor, thus possibly inducing arthritis16. It is therefore
plausible that SLE induces deficiencies in signaling chemical species,
particularlyMURNAc, that compose the cell walls of gastrointestinal
bacteria and that these deficiencies affect the progression of the dis-
ease and its collateral effects.
Significantly increased levels of ribose-1,5-bisphosphate (R1,5-dP;
629.8-fold increase; p 5 0.0034) were also observed in SLE patients
compared with HC subjects (Figure 3). This chemical species is an
intermediate in the production of 5-phospho-alpha-D-ribose-1-
diphosphate (PRPP), which is required for de novo purine and/or
pyrimidine biosynthesis and the synthesis of amino acids such as
histidine, tyrosine, and phenylalanine. In fact, an absence of 1-
(59-phosphoribosyl)-5-amino-4-(N-succinocarboxamide)-imidazole
(SAICAR) (p 5 0.0002) and slightly reduced production levels of
thiamine (1.9-fold reduction; p, 0.042), dUMP (1.7-fold reduction;
p 5 0.005), cytidine (1.5-fold reduction; p 5 0.0003), histidine (1.7-
fold reduction; p 5 0.0002), tyrosine (1.6-fold reduction; p 5 0.004),
and phenylalanine (1.7-fold; p 5 0.005) were observed in SLE patients
compared with healthy controls; note that the production of these
chemical species depends on the PRPP concentration.
We reasoned that the decreased activity of R1,5-dP-modifying
enzymes may lead to an accumulation of this substrate in SLE
patients; this in turnmay result in reduced production of metabolites
in the consequent metabolic steps. This was further confirmed by
targeted metabolomics where the extension of the biochemical pro-
duction of R1,5-dP from its reaction substrate ribose-5-phosphate
(Rib5P) as well as the consequent conversion to PRPP (see Figure 4)
Figure 3 | Box plots of key metabolite abundance levels in SLE patients compared with HC controls. The data and the statistical significances were
extracted from the data presented in Supplementary Table 5. The data are presented in the context of the KEGG metabolism pathways and indicate the
connection to each of the chemical species.
www.nature.com/scientificreports
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was evaluated using microbiotal protein extracts. Indeed, the following
four presumptive enzymes are implicated in these transformations: i)
phosphopentomutase (DeoB) and ribose 1,5-bisphosphokinase (PhnN)
transforming Rib5P to R1,5-dP; ii) phosphoglucomutase (Pgm) meta-
bolizing R1,5-dP to PRPP; and iii) ribose-phosphate pyrophosphoki-
nase (PrsA protein), which is implicated in the direct transformation
of Rib5P to PRPP. For this transformation, microbial protein extracts
from each of the SLE and HC subjects were obtained as previously
described16 for an activity test using a solution containing Rib5P (see
Methods section). The extent of Rib5P transformation and the pres-
ence of the R1,5-dP and PRPP reaction products were quantified by
LC-QqQ-MS (Figure 4). At the end of our assay, transformation of
Rib5P was demonstrated to a similar extent in both groups (54 to 40%
residual concentration). A higher concentration of R1,5-dP (1.7-fold)
and a significantly lower concentration of PRPP (7.0-fold) were
observed in SLE patients compared to HC subjects (Figure 4). This
confirms that the accumulation of R1,5-dP in SLE patients is most
likely due to a lower level of Pgm activity involved in the transforma-
tion of Rib5P to PRPP and not to the increased level of DeoB activity
that controls R1,5-dP biosynthesis from Rib5P.
Finally, we further noted that SLE patients accumulated mesopor-
phyrin IX (p, 0.0008) and protoporphyrin IX (p 5 0.0004), which
were absent in HC subjects (Supplementary Table 5). The fact that
mesoporphyrin IX is an inhibitor of heme synthesis and ferrochela-
tase activity is consistent with the accumulation of protoporphyrin
IX due to the presumptive inhibition of HemH proteins27. We sug-
gest that SLEmost likely decreases the iron uptake capacity of the gut
microbiota and may also inhibit heme synthesis. In agreement with
this, the serum ferritin level in SLE patients (n 5 18) was approxi-
mately 1.5-fold lower (according tomean values) than inHC subjects
(n 5 17) (Supplementary Table 3), and thus a relationship between
the deficiency in microbiotal iron uptake observed using a metabo-
lome-wide scan in SLE patients and a lower level of serum ferritin
could be suggested.
Higher BMIs in healthy controls promote the presence of bacteria
possessing the sialic acid catabolic pathway.Only 572 of 134,312 (or
0.43% of the total) mass features were statistically (p, 0.05) different
between healthy controls with high and low BMI values (Figure 1).
Therefore, when both groups were compared, the data indicated
that the impact of BMI on the gut microbiotal metabolite-wide flux
distribution and metabolism itself was moderately low. However,
among differences in other chemical species (Supplementary Table
5), an absence of N-acetylneuraminate (p 5 9.65e27; Supplementary
Table 5) was strongly associated with HC subjects with BMIs $
25.24 kg/m2 (sub-group ‘‘High BMI’’ in Figure 1). We reasoned
that the activities of N-acetylneuraminate lyases, encoded by the
sialic acid catabolic gene nahA28, which remove a pyruvate from
N-acetylneuraminate as a first step in the catabolism of sialic acid,
should be strongly depleted in lean individuals (here, BMI #
24.83 kg/m2). This may result in the accumulation of sialic acid
when compared with overweight or obese individuals (sub-group
‘‘High BMI’’).
To confirm this, the transformation of sialic acid into its corres-
ponding product N-acetyl-D-mannosamine was further examined
using a target metabolomics approach, in which the conversion of
sialic acid was followed using microbiotal protein extracts (see
Methods). The results revealed that lean HC patients were not able
to metabolize sialic acid, although it was transformed (only 13.8%
residual concentration at the end of the assay) to N-acetyl-D-man-
nosamine in obese HC subjects (Figure 4). This confirms that the
catabolism of sialic acid may be strongly diminished in lean indivi-
duals, most likely due to the absence or lower activity level of NahA
proteins.
Taken together, it is plausible that individuals from both high and
low BMI sub-groups may possess colonic bacteria that have the capa-
city to liberate sialic acid from the mucosa and transport it to bacterial
cells. However, individuals with high BMI (here,$25.24 kg/m2) may
have an additional genomic complement for the sialic acid catabolic
pathway (i.e., bacteria that produce NahA) that enables further meta-
bolism of sialic acid, whereas colonic bacteria from individuals with
low BMI (here,#24.83 kg/m2) may be unable to catabolize sialic acid.
Thus, sialic acid tends to accumulate in bacterial cells. This was con-
firmed by biochemical tests and target metabolomics analyses. These
data suggest that BMI (e.g., overweight/obesity) may not alter muco-
sal carbohydrate bioavailability but rather alters how liberated sugars
Figure 4 | Box plots of chemical species concentrations in reaction tests containing Rib5P (Panel A) and sialic acid (Panel B). The corresponding
peak areas were integrated using MassHunter Quantitative Analysis (B.05.00, Agilent). The final concentration of each analyte per sample was calculated
using the interpolation of each peak area in the corresponding calibration curve. Reaction conditions were as follows: 1 mL of 50 mM HEPES
pH 7.0, 0.1 mg of total protein, and 0.15 mg of Rib5P (Panel A) or 3.5 mg of sialic acid (Panel B). Reactions were incubated for 15 min at 25uC,
after which substrate conversion was examined by LC-QTOF-MS using the conditions described in the Methods section. All SLE and HC samples were
tested for substrate conversion in Panel A, whereas data for only the lean and obese HC subgroups are shown in B. Reactions without proteins but
with Rib5P or sialic acid were used as controls, and the initial concentrations are shown for comparative purposes.
www.nature.com/scientificreports
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are catabolized. We speculate that community members in indivi-
duals with high BMIs may efficiently consume mucosal carbohy-
drates, which in turn may induce growth and self-promoting host
inflammation compared with individuals with low BMI. Consistent
with this hypothesis, it has been reported recently that bacteria and
pathogens that are unable to catabolize sialic acid exhibit impaired
expansion28.
Discussion
We have demonstrated for the first time that the gastrointestinal
microbiota can be affected by immune factors. This association
was found at the level of the metabolite landscape of gut microbiota
(Figure 1) but not at the level of bacterial composition (Figure 2),
which suggests that SLE can influence the heterogeneous species
inhabiting the gut in such a concerted way that a distinctive meta-
bolic pattern arises. These results demonstrate that deficiencies in the
chemical species mediating cell signaling and regulation are among
themajor effects of SLE.We speculate that lowering quorum sensing,
cell-to-cell communication and cell wall biosynthesis, which are
known to be of global importance in microbial ecosystems19–24,
may be partially responsible for the concerted mechanism inducing
these common metabolic patterns. Such alterations may also act as
disease factors by promoting the immune response, as has been
suggested in the case of arthritis24,25. These alterations may also cause
alterations in specific cell-critical systems, such as nucleotide biosyn-
thesis, iron uptake and heme synthesis, without substantial loss of
metabolic robustness. However, further experimental evidence is
needed to confirm the cause and effect relationship between the
altered metabolites and the underlying SLE disease.
We also found that BMI has an effect at the level of the metabolite
landscape but not at the level of themicrobiota composition based on
16S rRNA gene survey. Interestingly, such changes were only notice-
able in healthy controls. The impact of BMI on metabolism itself is
also limited, and only select robust effects on the catabolism of sialic
acid were revealed. The fact that no effect on the production of
regulatory/signaling molecules and cell wall synthesis was observed
in HC individuals suggests that different mechanisms may be
responsible for generating the distinct metabolic patterns of SLE
and HC intestinal microbiota and that a regulatory/signaling res-
ponse may be one of the major causes linking the altered microbial
metabolites and SLE disease, where BMI did not have an effect.
Together, the evidence generated in this study demonstrates that
the gut microbiota functionality can be affected by immune and
weight factors. Also, it demonstrates that metabolome-wide assess-
ments may be a better indicator than 16S rRNA survey to enable not
only the segregation of different diseases and disorders (here, SLE
and overweight/obesity) but also the ranking of the effects of the
disease/disorder on microbiotal metabolism. As an example, we
demonstrated that an immune response, exemplified by SLE, is a
dominant factor compared to obesity in controlling the metabolism
of the intestinal microbiota. We believe that these findings, for which
no previous evidence exists in the scientific literature, potentially
open new research avenues for investigating the response mechan-
isms of human gut microbiota to a single or collective immune,
genetic, pathogenic, and dietary pressures, and more importantly,
the interaction and relative clinical importance of each of these
factors for the progression of different diseases and predispositions
to metabolic dysfunctions, such as metabolic syndrome in SLE
patients13.
Only 955 of 134,312 (or 0.72% of the total) and 572 of 134,312 (or
0.43% of the total) mass features were found to significantly differ
between the SLE and HC groups and between HC subjects with high
and lowBMI values, respectively. It is therefore important to evaluate
whether or not such subtle differences can be considered within a
common range. It is worth noting, however, that no report to date
has described the metabolomic profiling of either bacterial fecal
extracts or fecal fluids from patients with SLE; therefore, little is
known about whether the observed differences between SLE and
HC are within a common range. In the case of subjects that are
discordant for weight, few examples exist in the literature that have
examined fecal fluid metabolomes. Thus, it should be highlighted
that a recent report examining the cecal metabolome revealed that
only 65 out of a total of 10,515mass signals (or 0.7% of the total) were
significantly associated with a high-fat diet29. In a different study,
only 22 fecal metabolites have been shown to be differentially pro-
duced in monozygotic twin pairs that were discordant for weight18.
In cases of other pathophysiologies, using metabolite profiling of
fecal fluids, it was found that only: i) 18 fecal metabolites allowed
discrimination between ulcerative colitis and irritable bowel syn-
drome and healthy control patients30; ii) 99 allowed discrimination
of humanized and gnotobiotic mice, even though they possess quite
distinct microbiota (85% of genera and microbial species are differ-
ent)31; iii) 43 metabolites were found to differ when comparing
human, mouse and rat fecal metabolomes32; and iv) 22 metabolites
allow the segregation of patients with colorectal cancer compared to
healthy adults33. Therefore, based on bibliographic records in the
specialized literature, the subtle differences associated with SLE or
BMI reported in the present study can be considered within a com-
mon range observed for, or even few times higher than, those
observed for reported pathophysiologies.
The further question that arises is whether these subtle differences
in gut microbiota functionality are sufficient to have physiological
implications. Based on the data reported herein, it is plausible that
only selective effects in a number of key metabolites with major bio-
logical relevance/significance may be sufficient to induce gut home-
ostasis or alterations in gut microbiota functionality, even though the
impact on the global metabolome is moderate, regardless of the het-
erogeneities at the population level. The deficiencies observed in
chemical species participating in, for example, quorum sensing, cell-
to-cell communication and cell wall biosynthesis, which are known to
be of global importance in microbial ecosystems, agree with this hypo-
thesis. Having said that, it should be noted that in many cases, minor
differences, e.g., at the population level, have been demonstrated to
induce strong physiological changes. As an example, it has recently
been demonstrated that one or two strains are sufficient to drive major
changes in gastrointestinal and host (mouse) metabolic profiles where
up to 1012 microbial cells or more than 500 species may coexist31.
The effects of various pathophysiologies in the human gut metabo-
lome have been previously examined18,29–33. However, no clear asso-
ciations between fecal fluid metabolome patterns and individual
pathophysiologies (e.g., weight gain or the presence of a disease) were
previously observed; this was mainly due to the large inter-individual
variation. For example, the examination of fecal metabolomes from at
least 10 obese mice (body weight change: from 2 to 8 grams) revealed
heterogeneous distributions, and no clear clusters were visible at the
BMI level29. Such inter-individual variation was not observed in this
study, as mass signals within grouped subjects (SLE patients and HC
subjects with ‘‘low’’ or ‘‘high’’ BMI) were highly similar regardless of
age, disease duration, dietary intake, lifestyle-related factors or medical
history. One of the major differences from previous studies is that
herein we focused on the isolation of metabolites from microbes iso-
lated from stool material followed by a metabolome-wide scan, rather
than examining total fecal fluids. In relation to this examination, the
microbiota is the central bioreactor of the gastrointestinal tract, and a
dynamic interplay exists with the host and the environment7. As a
result of metabolic actions and environmental inputs, the gut envir-
onment and, in turn, the fluid fecal material contains a complex mix-
ture of metabolites provided through the diet, the host and intestinal
bacteria. Such complex mixtures are commonly investigated in meta-
bolomics studies18,29–33. Metabolites from intestinal bacteria, rather
than dietary and host metabolites, are required to maintain and repair
the large intestine and to support human health34. Therefore, any
www.nature.com/scientificreports
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knowledge related to metabolites that are directly produced or
adsorbed (from environmental inputs or the host) by gut microbes,
not those present in complex whole fecal fluids, may be of relevance
not only for investigating what is happening throughout the gut but
also for determining their role in pathophysiologies and human health.
We believe this investigation will provide information that can be
directly linked to complementary microbial data, i.e., 16S rRNA gene
profiles, which is difficult to achieve otherwise if non-microbial meta-
bolites (from the environment or host), which are commonly consid-
ered when working with whole fecal material, are investigated. In the
present study, metabolites from intestinal bacteria have been shown to
be good indicators of gut microbiota functionality under various
pathophysiologies, and they may be more effective than fecal fluids
as a read-out of pathophysiologically induced alterations. Note that
our study relates to metabolite levels inside gut bacterial cells, which
may have a different meaning than those in plasma and, to some
extent, in fecal fluids.
Finally, further research is required of the mechanisms that gen-
erate the distinct and robust gut microbial metabolic profiles dis-
cussed herein. This investigation will provide a deeper view on what
the microbiota do rather thanwho they are. We hypothesize that new
reliable clinical information and explanatory and mechanistic plaus-
ibility for these associations as well as new sensitive, predictive dis-
ease biomarkers of clinical relevance may arise when the microbiotal
metabolite landscape rather than heterogeneous species gut com-
position are investigated.
Methods
Chemicals and reagents. The following reagents were used: acetonitrile (HPLC-MS
grade, Sigma-Aldrich, Taufkirchen, Germany), formic acid (MS grade, Sigma-
Aldrich, Steinheim, Germany), L-methionine sulfone (Sigma-Aldrich, Taufkirchen,
Germany), sodium hydroxide (Panreac, Montcada I Reixac, Spain) and ammonia
(Panreac, Castellar del Valle`s, Barcelona, Spain). For reference masses, purine and
hexakis(1H,1H,3H-tetrafluoropropoxy)phosphazine (HP) from Agilent (API-TOF
reference mass solution kit) were used. All solutions were prepared using MilliQH
water (Millipore, Billerica, MA, USA).
Sample treatment for metabolite isolation. Fresh stool samples were collected from
each subject, frozen immediately, and stored at 280uC until they were processed. A
total of 34 samples were metabolome-typed using a combination of untargeted mass
spectrometry and two different and complementary separation techniques (liquid
chromatography-mass spectrometry [LC-ESI-QTOF-MS] and capillary
electrophoresis-mass spectrometry [CE-TOF-MS]). To facilitate this analysis,
microbial cells were separated from the fecal material, and the total microbial
metabolites were extracted from equal amounts of microbial cells per sample by
adapting a previously reported method4 and including a two-step extraction method
that was shown to produce the optimal extraction efficiency for both polar and
hydrophobic metabolites.
Briefly, microbial cells were separated from the fecal matrix bymixing 0.4 g of fecal
sample with 1.2 mL of phosphate-buffered saline (PBS) solution (153 w/v feces to
PBS ratio); following re-suspension (by 1 min of vigorous vortexing), the samples
were then centrifuged at 1,000 g at 4uC for 1 min to remove fecal debris. The
supernatant (0.6 mL) was transferred to a 2-mL Eppendorf tube and centrifuged at
13,000 g at 4uC for 5 min to pellet the cells. Immediately after isolating the microbial
cells, the cells were used for MeOH extraction by adding 1.2 mL of cold (280uC)
HPLC-grade MeOH. The samples were then vortex-mixed (for 10 s) again and
sonicated for 30 s (in a SonicatorH 3000; Misonix) at 15 W in an ice cooler (220uC).
This protocol was repeated twice more with a 5-min storage at 220uC between each
cycle, and the final pellet was removed following centrifugation at 12,000 g for 10 min
at 4uC. Immediately after the MeOH extracts were obtained, the MeOH solution was
stored at 280uC, and the remaining cell pellet was re-suspended in 1.2 mL of cold
(4uC) HPLC-grade H2O and subjected to 3 cycles of sonication for 20 s (in a
SonicatorH 3000; Misonix) at 15 W in ice water. The samples were incubated on ice
for 2 min between cycles. The final pellet was removed following centrifugation at
12,000 g for 10 min at 4uC. Immediately after the H2O and MeOH extracts were
obtained, a mixture was prepared by combining equal amounts (1 mL) of each of the
extracts. Once prepared, the final solution was stored in 20-mL penicillin vials at
280uC for use.
Two hundred microliters of the cellular extracts were mixed with 200 mL of acet-
onitrile to precipitate the proteins. This solution was then centrifuged at 13,000 rpm
at 4uC for 10 min to separate any solid impurities. The supernatants were removed
and filtered through 0.2-mm nylon syringe filters. Then, 100 mL were transferred to
analytical vials for LC-MS analysis. For CE-MS analysis, 70 mL of filtered extract were
evaporated to dryness using a Speedvac Concentrator, and each sample was then
reconstituted in 70 mL of MilliQH water containing an internal standard (0.2 mM L-
methionine sulfone) and 0.1 M formic acid.
Preparation of quality controls (QCs) for metabolomic fingerprinting. Because
the samples interact during the separation technique and MS, it is crucial to employ
quality controls (QCs) during LC-MS and CE-MS to ensure analytical
reproducibility. Indeed, QC samples are required at the beginning of the sequence to
stabilize the system and throughout the analytical runs at periodic intervals of time to
monitor variations in signal across time35. QC samples were prepared independently
for LC-MS and CE-MS by pooling and mixing equal volumes of each sample. After
gently vortexing, the mix was also filtered and subsequently transferred to an
analytical vial.
Metabolomic fingerprinting by LC-ESI-QTOF-MS. The metabolic profile was
achieved using a liquid chromatography system consisting of a degasser, a binary
pump, and an autosampler (1290 infinity, Agilent). Samples (0.5 mL) were applied to
a reversed-phase column (Zorbax Extend C18 50 3 2.1 mm, 3 mm; Agilent), which
was maintained at 60uC during the analysis. The system was operated at a flow rate of
0.6 mL/min with solvent A (water containing 0.1% formic acid) and solvent B
(acetonitrile containing 0.1% formic acid). The gradient was 5% B (0–1 min), 5 to
80% B (1–7 min), 80 to 100% B (7–11.5 min), and 100 to 5% B (11.5–12 min). The
systemwas finally held at 5% B for 3 min to re-equilibrate the system (15 min of total
analysis time). Data were collected in positive and negative ESI modes in separate
runs using QTOF (Agilent 6550 iFunnel). Analyses were performed in both positive
and negative ion modes. The positive mode was operated in full-scan mode fromm/z
50 to 1000. The capillary voltage was 3000 V with a scan rate of 1.0 spectrum per
second. The gas temperature was 250uC, the drying gas flow was 12 L/min and the
nebulizer was 52 psi. The MS-TOF parameters were as follows: fragmentor, 175 V;
skimmer, 65 V; and octopole radio frequency (OCT RF Vpp) voltage, 750 V. The
negative ion mode was operated in full-scan mode fromm/z 50 to 1100. The capillary
voltage was 3000 V with a scan rate of 1.0 spectrum per second. The gas temperature
was 250uC. The drying gas flow was 12 L/min, and the nebulizer was 52 psi. TheMS-
TOF parameters included the following: fragmentor, 250 V; skimmer, 65 V; and
octopole radio frequency voltage, 750 V. During the analyses, two reference masses
were used: 121.0509 (detected m/z [C5H4N4 1 H]1) and 922.0098 (detected m/z
[C18H18O6N3P3F24 1 H]1) in positive mode and 112.9855 (detected m/z [C2O2F3-
H]2) and 1033.9881 (detected m/z [C18H18O6N3P3F24 1 TFA-H]2) in negative
mode. The references were continuously infused into the system, enabling constant
mass correction. Samples were analyzed in randomized runs, during which they were
incubated in an autosampler at 4uC. The analytical runs for both polarities were set up
starting with the analysis of ten QCs followed by the samples; a QC sample was
injected in between blocks of five samples until the end of the run.
Metabolomic fingerprinting by CE-TOF-MS.A capillary electrophoresis apparatus
(7100 Agilent) coupled to a TOF Mass Spectrometer (6224 Agilent) was employed.
The CEmode was controlled by ChemStation software (B.04.03, Agilent), and theMS
mode was controlled by Mass Hunter Workstation Data Analysis (B.02.01, Agilent).
The separation occurred in a fused-silica capillary (Agilent: total length, 100 cm;
internal diameter, 50 mm). All separations were performed in normal polarity with a
background electrolyte containing 0.8 M formic acid in 10% methanol (v/v) at 20uC.
New capillaries were pre-conditioned with a flush of 1.0 M NaOH for 30 min
followed by MilliQH water for 30 min and the background electrolyte for 30 min.
Prior to each analysis, the capillary was conditioned with a flush of background
electrolyte for 5 min. The sheath liquid (6 mL/min) was MeOH:H2O (151)
containing 1.0 mM formic acid with two references masses of m/z 121.0509
([C5H4N4 1 H]1) and m/z 922.0098 ([C18H18O6N3P3F24 1 H]1), which enabled
correction and higher mass accuracy during MS. Samples were hydrodynamically
injected at 50 mBar for 50 s. The stacking was performed by applying the background
electrolyte at 100 mBar for 10 s. The separation voltage was 30 kV, and the internal
pressure was 25 mBar; the analyses were performed within 35 min. The MS
parameters included the following: fragmentor, 100 V; skimmer, 65 V; octopole,
750 V; drying gas temperature, 200uC; flow rate, 10 L/min; and capillary voltage,
3500 V. Data were acquired in positive mode with a full scan fromm/z 85 to 1000 at a
rate of 1.41 scan/s. The analytical run started with an analysis of five QCs followed by
the samples; a QC sample was injected in between blocks of five samples until the end
of the run.
Metabolomic data treatment. The Feature Extraction tool in the Mass Hunter
Qualitative Analysis software (B.05.00, Agilent) was used. The alignment of the raw
data was performed using MassProfiler Professional software (B.12.01, Agilent). The
variables were then filtered. Data present in at least 50% of the QCs, with coefficients
of variation less than 30% across the QCs, were selected, and models were
subsequently built using SIMCA-P1 software (12.0.1.0, Umetrics; Figure 1). Based
on the PCA and the patient’s BMI, sample HC4 was rejected prior to statistical
analysis. Subsequently, any missing values were replaced by the mean (if the variable
was present in more than 2/3 of the samples per group) or by half of the minimum
value (if the variable was present in 1/3 to 2/3 of the samples per group). Missing
variables that were present in less than 1/3 of samples per group were denoted as zero.
Finally, groups were compared in pairs (SLE vs. HC andHCh [HCwith high BMI] vs.
HCl [HC with low BMI]) using Mann-Whitney U tests or t-tests followed by
Bonferroni corrections to minimize false positives (corrected p value #0.05;
MATLAB 7.10.0.499). The resulting list of accurate masses that significantly differed
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between groups was searched using the CEU Mass Mediator search tool (http://
biolab.uspceu.com/mediator; error 6 5 ppm). This procedure was performed
independently for each analytical platform.
Note that the robustness of the analytical procedure was demonstrated by the tight
clustering of the QCs (Figure 1), showing that the separation between groups was due
to actual biological variability and was not random.
16S rRNA microbiota analysis. The QIIME software suite was used to construct a
UniFrac similarity matrix of all 16S rRNA profiling samples included in this study
based on their operational taxonomic unit (OTU) profiles11. This similarity matrix
was processed to obtain a three-dimensional principal coordinate analysis (PCoA)
where the percentages shown along the axes represent the proportion of
dissimilarities between samples captured by the axes (Figure 2). The raw sequences
reported in this article have been deposited in the NCBI Short Read Archive (SRA)
(study accession number: SRP028162)11.
Biochemical tests by targeted metabolomics. Protein extracts from each of the SLE
patients and HD subjects were obtained and used for activity tests as previously
described17. The extent of transformation of Rib5P to R1,5-dP and to PRPP was
quantified in a solution containing 1 mL of 50 mM 4-(2-hydroxyethyl piperazine-1-
ethanesulfonic acid (HEPES), pH 7.0, 0.15 mg/mL ribose-5-phosphate and 0.1 mg/
mL total protein. Similarly, transformation of sialic acid (3.5 mg/mL) to N-acetyl-D-
mannosamine was performed under similar conditions. Reactions were kept for a
total time of 15 min at 25uC, and substrate conversion was examined by LC-QqQ-MS
as described below. Reactions without proteins and substrates were used as controls;
they were subsequently treated in the same manner as samples.
Sample treatment. Prior to analysis, the samples were diluted 153 with MilliQH water
(dilution factor 4), and a pool of samples was prepared by extracting 10 mL from each
vial. Independently, a mix of standards (Rib5P, R1,5-dP, PRPP, N-acetyl-neuraminic
acid and N-acetyl-D-mannosamine and N-acetyl-neuraminic acid; all from Sigma
Chemical Co., St. Louis, MO) was prepared from independent solutions of each
compound, with a final concentration of 10 ppm (mg/L) in MilliQH water, and
subsequently diluted to 7.5, 5, 2.5 and 1 ppm (mg/L).
LC-QqQ-MS. Each analysis was achieved using a liquid chromatography system
consisting of a degasser, binary pump and autosampler (1290 Infinity, Agilent
Technologies, Santa Clara, CA, USA) coupled to a triple quadrupole mass spectro-
meter (6460, Agilent Technologies). A KinetexH HILIC column (150 3 2.1 mm,
2.6 mm, Phenomenex, Torrance, CA, USA) was maintained at 50uC during the
analysis. The system was operated at a flow rate of 0.6 mL/min with solvent A (water
with 5 mMof ammonium formate, pH 6.8) and solvent B (acetonitrile). The gradient
was as follows: 75% B (0–0.5 min), 75 to 0% B (0.5–5 min), 0% B (5–6 min) and 0 to
75% B (6–7 min), keeping the re-equilibration at 75% B for 4 min (11 min of total
analysis time). Data were collected in negative MRMmode. The MS-ESI parameters
were optimized as follows: capillary voltage, 2500 V; gas temperature, 200uC; drying
gas flow, 8 L/min; nebulizer, 48 psi; and nozzle voltage, 0 V. The MS-QqQ para-
meters were as follows: fragmentor, 116 V; dwell time, 20 ms; and cell accelerator
voltage, 7 V. The m/z quantification transition for each compound was as follows:
Rib5P (229-97), R1,5-dP (309-97), PRPP (388.9-79), N-acetyl-mannosamine (220.1-
59.1) and N-acetyl-neuraminic acid (308.1-87). The analytical run started with the
analysis of ten injections of the pool to equilibrate the chromatographic system and
was followed by the samples in a randomized order. Samples were maintained at 4uC
throughout the run, and 20 mL of each sample were injected.
Study approval. Ethical approval for this study (reference code AGL2010-14952;
grant title ‘‘Towards better understanding of gut microbiota functionality in some
immune disorders’’) was obtained from the Bioethics Committee of CSIC and from
the Regional Ethics Committee for Clinical Research (Servicio de Salud del Principado
de Asturias) in compliance with the Declaration of Helsinki. All determinations were
performed with fully informed written consent from all participants involved in this
study. All experiments were performed in accordance with approved guidelines and
regulations.
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